

Date: July 09, 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Scrip Code: 544292	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: ONESOURCE
--	--

Ref: Intimation under regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Dear Sir/ Madam,

We refer to the intimation made earlier today by Dr. Reddy’s Laboratories (DRL) regarding delay in commercial supplies of Semaglutide for a certain period of time and our earlier communications on our tie-up with DRL as a Manufacturing Partner for Generic Semaglutide Injection.

In this regard, we wish to clarify that the delay in commercial supplies as disclosed by DRL does not have any material impact, financially or otherwise, on our operations.

While we stay committed to our long-standing valuable partnership with DRL, we have enough demand for the product from other customers, including for Canada, and our capacities are fully committed. We are also adding significant new capacities starting current quarter and later in the year, in line with our expansion plans, as earlier communicated and thus will be in a position to supply all the demand of DRL as soon as they are ready.

We remain focused on executing our growth plans and serving our global customers with high standards of quality, reliability and supply continuity.

This is for your information and records.

For and on behalf of
OneSource Specialty Pharma Limited

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635